Miromatrix Medical, Inc. (MIRO)
| Market Cap | 141.84M |
| Revenue (ttm) | 41,550 |
| Net Income (ttm) | -7.79M |
| Shares Out | 17.73M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | n/a |
| Last Price | n/a |
| Previous Close | n/a |
| Change ($) | n/a |
| Change (%) | n/a |
| Day's Open | n/a |
| Day's Range | n/a |
| Day's Volume | n/a |
| 52-Week Range | n/a |
News
Miromatrix Medical, Inc. has filed to go public with an IPO on the NASDAQ.
About MIRO
Miromatrix Medical is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. We have developed a proprietary perfusion technology platform for bioengineering organs that we believe will efficiently scale to address the shortage of available human organs. Our perfusion decellularization and recellularization technology platform includes 118 issued and 35 pending patent applications, with protection in the United States and major markets worldwide. Our... [Read more...]
| Industry Biological Products | IPO Date Jun 24, 2021 |
| CEO Jeff Ross | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol MIRO |
Financial Performance
In 2020, MIRO's revenue was $46,530, a decrease of -81.39% compared to the previous year's $250,000. Losses were -$10.31 million, 154.8% more than in 2019.